A systematic review of health-related quality of life in cutaneous melanoma.
A systematic review of health-related quality of life in cutaneous melanoma.
复制标题
皮肤黑色素瘤中与健康相关的生活质量的系统评价。
DOI：
10.1093/annonc/mdp255
复制
发表时间：
2009-08
期刊：
影响因子：
--
通讯作者：
Nijsten T
中科院分区：
文献类型：
--
作者：
Cornish D;Holterhues C;van de Poll-Franse LV;Coebergh JW;Nijsten T
黑色素瘤可以被认为是一种新兴的慢性疾病，可能会大大影响患者的生活。作者系统地回顾了关于健康相关生活质量（HRQOL）和黑色素瘤的现有文献。在综述和选定的研究中，手动检索参考文献列表。根据14项先前发表的标准对合格研究的质量进行评价。在158篇摘要中，对44篇文章进行了评价，从而选出了13篇英文研究（2001年至2008年发表）。大多数研究评估了来自专业中心的患者，这些患者具有不同但相对晚期的疾病阶段。最常用的工具是SF-36和EORTC QLQ-C30。最近，出于临床试验目的，引入了黑色素瘤特异性HRQOL问卷[FACT-Melanoma（FACT-M）]。它表明，大约三分之一的黑色素瘤患者经历了相当程度的痛苦，主要是在诊断和治疗后。全身治疗在短期内对HRQOL产生负面影响，但长期影响程度较小。健康状况和患者的心理特征与较高水平的HRQOL损害相关。作者发现，黑色素瘤对患者HRQOL的影响与其他癌症相当。准确评估黑色素瘤患者的HRQOL损害是至关重要的，因为它可能会影响疾病管理，包括治疗和额外的咨询，未来的预防行为，甚至可能是预后。
Melanoma can be considered an emerging chronic disease that may considerably affect patients’ lives. The authors systematically reviewed the available literature on health-related quality of life (HRQOL) and melanoma. Of reviews and the selected studies, reference lists were hand-searched. The quality of the eligible studies was appraised based on 14 previously published criteria. Of the 158 abstracts, 44 articles were appraised, resulting in 13 selected studies written in English (published between 2001 and 2008). Most studies assessed patients from specialised centres with varying, but relatively advanced, disease stages. The most commonly used instruments were the SF-36 and EORTC QLQ-C30. Recently, a melanoma-specific HRQOL questionnaire [FACT-Melanoma (FACT-M)] was introduced for clinical trial purposes. It showed that approximately one-third of melanoma patients experienced considerable levels of distress, mostly at the time of diagnosis and following treatment. Systemic therapies affected HRQOL negatively in the short term, but to a lesser extent in the long term. Health status and patients’ psychological characteristics are associated with higher levels of HRQOL impairment. The authors found that the impact of melanoma on patients’ HRQOL is comparable to that of other cancers. Accurately assessing HRQOL impairment in melanoma patients is pivotal, as it may affect disease management, including therapy and additional counselling, future preventive behaviour and perhaps even prognosis.
登录
查看更多内容
DOI：
10.1016/j.bjps.2005.01.010
发表时间：
2006-01-01
影响因子：
2.7
作者：
Al-Shakhli, H;Harcourt, D;Kenealy, J
通讯作者：
Kenealy, J
影响因子：
6.2
作者：
Cormier, Janice N.;Ross, Merrick I.;Palmer, J. Lynn
通讯作者：
Palmer, J. Lynn
影响因子：
3.6
作者：
Devine, D;Parker, PA;Cohen, L
通讯作者：
Cohen, L
影响因子：
50.5
作者：
Lehto, US;Ojanen, M;Kellokumpu-Lehtinen, P
通讯作者：
Kellokumpu-Lehtinen, P
影响因子：
13.8
作者：
Stam-Posthuma, JJ;van Duinen, C;Bergman, W
通讯作者：
Bergman, W